Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Trump Chooses Gottlieb to Run FDA; Pharma Breathes Sigh of Relief

Toni Clarke  |  March 13, 2017

WASHINGTON (Reuters)—U.S. President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, the White House said on Friday. If confirmed by the Senate, Gottlieb would be in charge of implementing Trump’s plan to dramatically cut regulations governing…

U.S. Doctors in Training to Work Longer Hours Under New Guidelines

Andrew M. Seaman  |  March 13, 2017

(Reuters Health)—Days may get a lot longer for some doctors in training after the group that oversees medical education in the U.S. rolled back controversial rules limiting the number of hours first-year residents may work. Beginning July 1, doctors in their first year of training after medical school may once again care for patients for…

Moderate Alcohol Intake Decreases SLE Risk in Women

Arthritis Care & Research  |  March 8, 2017

Beer, wine, liquor—alcohol contains elements that suppress systemic inflammation, and its consumption has been linked to reduced risk of cardiovascular disease and RA. A recent analysis examined the effect of alcohol on SLE risk in women from the two Nurses’ Health Study cohorts. The results: Researchers found an inverse association between moderate alcohol consumption and SLE risk—with a 39% reduction in SLE risk among women who consumed about half a drink of alcohol daily…

Studies Highlight Gender, Racial Inequalities in Medical Profession

Andrew M. Seaman  |  March 7, 2017

(Reuters Health)—Women and minorities face more barriers to getting ahead in their medical careers, both early in training and later on, researchers say. In one study, Dr. Julie Boiko of the University of California, San Francisco, and colleagues found that women are underrepresented among speakers at grand rounds. This was true for all but two…

Trump Backs House Healthcare Plan, Says Open to Negotiations

Reuters Staff  |  March 7, 2017

WASHINGTON (Reuters)—U.S. President Donald Trump on Tuesday backed a draft Republican proposal to dismantle Obamacare that was unveiled Monday, saying the proposed healthcare legislation was “out for review and negotiation.” Trump, in a tweet on Tuesday morning, described the bill proposed by fellow Republicans in the House of Representatives as “Our wonderful new healthcare bill.”…

U.S. Republicans Unveil Plan to Dismantle Obamacare, Critics Pounce

Susan Cornwell & Yasmeen Abutaleb  |  March 7, 2017

WASHINGTON (Reuters)—Long-awaited legislation to dismantle Obamacare was unwrapped on Monday by U.S. Republicans, who called for ending health insurance mandates and rolling back extra healthcare funding for the poor in a package that drew immediate fire from Democrats. In a battle waged since the 2010 passage of the Affordable Care Act, Democratic President Barack Obama’s…

U.S. Republicans Expected to Unveil Healthcare Bill This Week

Susan Cornwell  |  March 6, 2017

WASHINGTON (Reuters)—Republican U.S. lawmakers expect to unveil this week the text of long-awaited legislation to repeal and replace the Obamacare healthcare law, one of President Donald Trump’s top legislative priorities, a senior Republican congressional aide said on Sunday. Since taking office in January, Trump has pressed his fellow Republicans who control Congress to act quickly…

Infliximab Use Not Tied to Malignancy in Pediatric IBD

David Douglas  |  March 6, 2017

NEW YORK (Reuters Health)—Immunosuppressive therapy with infliximab (Remicade) for inflammatory bowel disease (IBD) in pediatric patients is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis (HLH), according to a Janssen study. Dr. Jeffrey S. Hyams, who worked on the study, calls the finding “reassuring.” He adds in an email to Reuters Health, “our…

Comparative Assessment of the Different ACR/EULAR Remission Definitions for RA for Their Use as Clinical Trial End Points

Arthritis & Rheumatology  |  February 28, 2017

Significant advances have been made in the treatment of RA over the past 20 years, and with the hope of developing even more effective therapeutics, achieving a very low level of disease activity, such as remission, is an important outcome to be examined. The ACR and EULAR have defined remission using Boolean- or index-based criteria. The researchers undertook this study to compare definitions of remission to inform choice of end points for future RA clinical trials and included in their comparison the remission criterion of a score of ≤2.8 on the Clinical Disease Activity Index…

Volatility of the Gut Microbiome Tied to IBD

Marilynn Larkin  |  February 21, 2017

NEW YORK (Reuters Health)—Fluctuations in the gut microbiome over time could underlie inflammatory bowel disease (IBD), including Crohn’s and ulcerative colitis, researchers suggest. “Both the state and the dynamics of the human gut microbiome in healthy individuals are highly personalized. Although cross-sectional studies have revealed dysbiosis of the gut microbiome in IBD, little is known…

  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences